Christos Iavazzo1, Ioannis D Gkegkes2, Nikolaos Vrachnis3. 1. Gynaecological Oncology Department, Christie Hospital, Manchester, United Kingdom. 2. First Department of Surgery, General Hospital of Attica "KAT", Athens, Greece. 3. Second Department of Obstetrics and Gynecology, University of Athens Medical School, Aretaieio Hospital, Athens, Greece.
Abstract
OBJECTIVE: The presence of deleterious mutations in breast cancer (BRCA)-1 or BRCA-2 gene has a decisive influence on the development of various types of neoplasms, such as breast, ovarian, tubal, and peritoneal cancers. Primary peritoneal cancer is an aggressive malignancy which, due to the absence of a specific screening test, cannot be diagnosed in its early stages. As a risk-reducing option, prophylactic bilateral salpingo-oophorectomy and mastectomy are often proposed in BRCA gene carriers. The effectiveness of a preventive surgical treatment is, however, unclear in the development of peritoneal cancer. MATERIAL AND METHODS: An extensive electronic search was performed in PubMed, Scopus, and Cochrane databases. RESULTS: The total number of patients who underwent prophylactic bilateral salpingo-oophorectomy was 1,830, of whom 28 presented with peritoneal cancer (1.53%). The age of the included patients ranged from 48 to 61 years. BRCA-1 was present in 9 out of 28 patients and BRCA-2 in 2 patients, while the type of BRCA was unclear in 17 patients. Salpingo-oophorectomy was performed in 23 out of 28 patients, while oophorectomy was carried out in 5 patients. The interval from initial risk-reducing surgical treatment to the presentation of peritoneal cancer ranged from 12 to 84 months. CONCLUSION: Modification of the follow-up guidelines and increase in healthcare providers' awareness may reduce the risk of peritoneal cancer.
OBJECTIVE: The presence of deleterious mutations in breast cancer (BRCA)-1 or BRCA-2 gene has a decisive influence on the development of various types of neoplasms, such as breast, ovarian, tubal, and peritoneal cancers. Primary peritoneal cancer is an aggressive malignancy which, due to the absence of a specific screening test, cannot be diagnosed in its early stages. As a risk-reducing option, prophylactic bilateral salpingo-oophorectomy and mastectomy are often proposed in BRCA gene carriers. The effectiveness of a preventive surgical treatment is, however, unclear in the development of peritoneal cancer. MATERIAL AND METHODS: An extensive electronic search was performed in PubMed, Scopus, and Cochrane databases. RESULTS: The total number of patients who underwent prophylactic bilateral salpingo-oophorectomy was 1,830, of whom 28 presented with peritoneal cancer (1.53%). The age of the included patients ranged from 48 to 61 years. BRCA-1 was present in 9 out of 28 patients and BRCA-2 in 2 patients, while the type of BRCA was unclear in 17 patients. Salpingo-oophorectomy was performed in 23 out of 28 patients, while oophorectomy was carried out in 5 patients. The interval from initial risk-reducing surgical treatment to the presentation of peritoneal cancer ranged from 12 to 84 months. CONCLUSION: Modification of the follow-up guidelines and increase in healthcare providers' awareness may reduce the risk of peritoneal cancer.
Authors: C Bethan Powell; Lee-may Chen; Jane McLennan; Beth Crawford; Charles Zaloudek; Joseph T Rabban; Dan H Moore; John Ziegler Journal: Int J Gynecol Cancer Date: 2011-07 Impact factor: 3.437
Authors: Amy Finch; Mario Beiner; Jan Lubinski; Henry T Lynch; Pal Moller; Barry Rosen; Joan Murphy; Parviz Ghadirian; Eitan Friedman; William D Foulkes; Charmaine Kim-Sing; Teresa Wagner; Nadine Tung; Fergus Couch; Dominique Stoppa-Lyonnet; Peter Ainsworth; Mary Daly; Babara Pasini; Ruth Gershoni-Baruch; Charis Eng; Olufunmilayo I Olopade; Jane McLennan; Beth Karlan; Jeffrey Weitzel; Ping Sun; Steven A Narod Journal: JAMA Date: 2006-07-12 Impact factor: 56.272
Authors: Paul A M Meeuwissen; Caroline Seynaeve; Cecile T M Brekelmans; Hanne J Meijers-Heijboer; Jan G M Klijn; Curt W Burger Journal: Gynecol Oncol Date: 2005-05 Impact factor: 5.482
Authors: Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit Journal: N Engl J Med Date: 2002-05-20 Impact factor: 91.245
Authors: Joseph T Rabban; Ellen Krasik; Lee-May Chen; Catherine B Powell; Beth Crawford; Charles J Zaloudek Journal: Am J Surg Pathol Date: 2009-12 Impact factor: 6.394
Authors: Welmoed Reitsma; Geertruida H de Bock; Jan C Oosterwijk; Joost Bart; Harry Hollema; Marian J E Mourits Journal: Eur J Cancer Date: 2012-08-21 Impact factor: 9.162
Authors: Noah D Kauff; Susan M Domchek; Tara M Friebel; Mark E Robson; Johanna Lee; Judy E Garber; Claudine Isaacs; D Gareth Evans; Henry Lynch; Rosalind A Eeles; Susan L Neuhausen; Mary B Daly; Ellen Matloff; Joanne L Blum; Paul Sabbatini; Richard R Barakat; Clifford Hudis; Larry Norton; Kenneth Offit; Timothy R Rebbeck Journal: J Clin Oncol Date: 2008-02-11 Impact factor: 44.544
Authors: Ying L Liu; Kelsey Breen; Amanda Catchings; Megha Ranganathan; Alicia Latham; Deborah J Goldfrank; Rachel N Grisham; Kara Long Roche; Melissa K Frey; Dennis S Chi; Nadeem Abu-Rustum; Carol Aghajanian; Kenneth Offit; Zsofia K Stadler Journal: JCO Oncol Pract Date: 2021-09-28
Authors: George U Eleje; Ahizechukwu C Eke; Ifeanyichukwu U Ezebialu; Joseph I Ikechebelu; Emmanuel O Ugwu; Onyinye O Okonkwo Journal: Cochrane Database Syst Rev Date: 2018-08-24
Authors: Emma J Crosbie; Nicola Flaum; Elaine F Harkness; Richard D Clayton; Cathrine Holland; Pierre Martin-Hirsch; Nick Wood; Patrick Keating; Emma R Woodward; Fiona Lalloo; Paul Donnai; Richard J Edmondson; D Gareth Evans Journal: Int J Cancer Date: 2020-11-11 Impact factor: 7.396